HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood
Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing
and stem cell storage services, today announced that in response to
the non-binding proposal letter dated March
2, 2021 received by the Company's Board of Directors (the
"Board") from Alternate Ocean Investment Company Limited
("Alternate Ocean"), pursuant to which Alternate Ocean, acting on
behalf of the fund (the "Acquirer") that it manages and/or advises,
proposes to acquire all of the outstanding ordinary shares of the
Company for US$5.00 per ordinary
share in cash, subject to certain conditions. The Board has formed
a special committee of independent directors who are not affiliated
with Alternate Ocean (the "Special Committee") to evaluate such
proposal. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken
Lu, Mr. Jack Chow and Mr.
Jacky Cheng, each of whom currently
serves as an independent director on the Board, with Mr. Chen
serving as the chair of the Special Committee.
The Company cautions its shareholders and others considering
trading its ordinary shares that no decisions have been made with
respect to the Company's response to the proposed transaction. The
proposed transaction is still subject to various conditions,
including but not limited to, completion of due diligence, parties
entering into definitive agreement, and/or each of the Acquirer and
the Company obtaining its relevant regulatory and shareholders'
approval. There can be no assurance that any definitive offer will
be made, that any agreement will be executed or that this or any
other transaction will be approved or consummated.
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses. Global
Cord Blood Corporation provides cord blood collection, laboratory
testing, hematopoietic stem cell processing and stem cell storage
services. For more information, please visit the Company's website
at: http://www.globalcordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or other comparable
terminology. These statements are only predictions, uncertainties
and other factors may cause the Company's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. The information in this press release is not intended
to project future performance of the Company. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company does not guarantee future
results, levels of activity, performance or achievements. The
Company expectations are as of the date this press release is
issued, and the Company does not intend to update any of the
forward-looking statements after the date this press release is
issued to conform these statements to actual results, unless
required by law.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (+1) 646-405-5185
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-announces-formation-of-a-special-committee-to-evaluate-non-binding-proposal-301247163.html
SOURCE Global Cord Blood Corporation